Cargando…

Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors

Heterogeneity of cancer means many tumorigenic genes are only aberrantly expressed in a subset of patients and thus follow a bimodal distribution, having two modes of expression within a single population. Traditional statistical techniques that compare sample means between cancer patients and healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Moody, Laura, Xu, Guanying Bianca, Pan, Yuan-Xiang, Chen, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187341/
https://www.ncbi.nlm.nih.gov/pubmed/35639779
http://dx.doi.org/10.1371/journal.pcbi.1010109
_version_ 1784725146863403008
author Moody, Laura
Xu, Guanying Bianca
Pan, Yuan-Xiang
Chen, Hong
author_facet Moody, Laura
Xu, Guanying Bianca
Pan, Yuan-Xiang
Chen, Hong
author_sort Moody, Laura
collection PubMed
description Heterogeneity of cancer means many tumorigenic genes are only aberrantly expressed in a subset of patients and thus follow a bimodal distribution, having two modes of expression within a single population. Traditional statistical techniques that compare sample means between cancer patients and healthy controls fail to detect bimodally expressed genes. We utilize a mixture modeling approach to identify bimodal microRNA (miRNA) across cancers, find consistent sources of heterogeneity, and identify potential oncogenic miRNA that may be used to guide personalized therapies. Pathway analysis was conducted using target genes of the bimodal miRNA to identify potential functional implications in cancer. In vivo overexpression experiments were conducted to elucidate the clinical importance of bimodal miRNA in chemotherapy treatments. In nine types of cancer, tumors consistently displayed greater bimodality than normal tissue. Specifically, in liver and lung cancers, high expression of miR-105 and miR-767 was indicative of poor prognosis. Functional pathway analysis identified target genes of miR-105 and miR-767 enriched in the phosphoinositide-3-kinase (PI3K) pathway, and analysis of over 200 cancer drugs in vitro showed that drugs targeting the same pathway had greater efficacy in cell lines with high miR-105 and miR-767 levels. Overexpression of the two miRNA facilitated response to PI3K inhibitor treatment. We demonstrate that while cancer is marked by considerable genetic heterogeneity, there is between-cancer concordance regarding the particular miRNA that are more variable. Bimodal miRNA are ideal biomarkers that can be used to stratify patients for prognosis and drug response in certain types of cancer.
format Online
Article
Text
id pubmed-9187341
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-91873412022-06-11 Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors Moody, Laura Xu, Guanying Bianca Pan, Yuan-Xiang Chen, Hong PLoS Comput Biol Research Article Heterogeneity of cancer means many tumorigenic genes are only aberrantly expressed in a subset of patients and thus follow a bimodal distribution, having two modes of expression within a single population. Traditional statistical techniques that compare sample means between cancer patients and healthy controls fail to detect bimodally expressed genes. We utilize a mixture modeling approach to identify bimodal microRNA (miRNA) across cancers, find consistent sources of heterogeneity, and identify potential oncogenic miRNA that may be used to guide personalized therapies. Pathway analysis was conducted using target genes of the bimodal miRNA to identify potential functional implications in cancer. In vivo overexpression experiments were conducted to elucidate the clinical importance of bimodal miRNA in chemotherapy treatments. In nine types of cancer, tumors consistently displayed greater bimodality than normal tissue. Specifically, in liver and lung cancers, high expression of miR-105 and miR-767 was indicative of poor prognosis. Functional pathway analysis identified target genes of miR-105 and miR-767 enriched in the phosphoinositide-3-kinase (PI3K) pathway, and analysis of over 200 cancer drugs in vitro showed that drugs targeting the same pathway had greater efficacy in cell lines with high miR-105 and miR-767 levels. Overexpression of the two miRNA facilitated response to PI3K inhibitor treatment. We demonstrate that while cancer is marked by considerable genetic heterogeneity, there is between-cancer concordance regarding the particular miRNA that are more variable. Bimodal miRNA are ideal biomarkers that can be used to stratify patients for prognosis and drug response in certain types of cancer. Public Library of Science 2022-05-31 /pmc/articles/PMC9187341/ /pubmed/35639779 http://dx.doi.org/10.1371/journal.pcbi.1010109 Text en © 2022 Moody et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Moody, Laura
Xu, Guanying Bianca
Pan, Yuan-Xiang
Chen, Hong
Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors
title Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors
title_full Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors
title_fullStr Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors
title_full_unstemmed Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors
title_short Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors
title_sort genome-wide cross-cancer analysis illustrates the critical role of bimodal mirna in patient survival and drug responses to pi3k inhibitors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187341/
https://www.ncbi.nlm.nih.gov/pubmed/35639779
http://dx.doi.org/10.1371/journal.pcbi.1010109
work_keys_str_mv AT moodylaura genomewidecrosscanceranalysisillustratesthecriticalroleofbimodalmirnainpatientsurvivalanddrugresponsestopi3kinhibitors
AT xuguanyingbianca genomewidecrosscanceranalysisillustratesthecriticalroleofbimodalmirnainpatientsurvivalanddrugresponsestopi3kinhibitors
AT panyuanxiang genomewidecrosscanceranalysisillustratesthecriticalroleofbimodalmirnainpatientsurvivalanddrugresponsestopi3kinhibitors
AT chenhong genomewidecrosscanceranalysisillustratesthecriticalroleofbimodalmirnainpatientsurvivalanddrugresponsestopi3kinhibitors